180 related articles for article (PubMed ID: 32163103)
1. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
Kim RS; Yaghy A; Wilde LR; Shields CL
JAMA Ophthalmol; 2020 Apr; 138(4):418-419. PubMed ID: 32163103
[No Abstract] [Full Text] [Related]
2. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
4. A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Perrone S; Ortu La Barbera E; Viola F; Cipollone E; Scerpa MC; Siniscalchi R; Ottone T; Voso MT; Cimino G
Chemotherapy; 2021; 66(4):134-138. PubMed ID: 34515081
[TBL] [Abstract][Full Text] [Related]
5. Gilteritinib Changes AML Landscape.
Saleh N
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469903
[No Abstract] [Full Text] [Related]
6. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
[TBL] [Abstract][Full Text] [Related]
8. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
[TBL] [Abstract][Full Text] [Related]
9. RNA-based
Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
[TBL] [Abstract][Full Text] [Related]
10. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation.
Akahane D; Moriyama M; Yoshizawa S; Katagiri S; Fujimoto H; Gotoh A
Geriatr Gerontol Int; 2019 Oct; 19(10):1063-1064. PubMed ID: 31602758
[No Abstract] [Full Text] [Related]
12. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
13. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Gorcea CM; Burthem J; Tholouli E
Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296
[TBL] [Abstract][Full Text] [Related]
14. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
Smith CC; Levis MJ; Perl AE; Hill JE; Rosales M; Bahceci E
Blood Adv; 2022 Apr; 6(7):2144-2155. PubMed ID: 35130342
[TBL] [Abstract][Full Text] [Related]
15. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N
Leuk Res; 2024 Jun; 141():107505. PubMed ID: 38692232
[TBL] [Abstract][Full Text] [Related]
17. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
Miyajima T; Harada S; Ogasawara R; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Chi S; Minami Y; Kondo T
Rinsho Ketsueki; 2022; 63(1):51-54. PubMed ID: 35135952
[TBL] [Abstract][Full Text] [Related]
19. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
[TBL] [Abstract][Full Text] [Related]
20. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
